Engineering yeast for producing human glycoproteins: Where are we now?

Future Microbiology

Volumn 10, Issue 1, 2015, Pages 21-34

  Laukens, Bram ^a   De Visscher, Charlotte ^a   Callewaert, Nico ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

N glycosylation engineering; O glycosylation engineering; Pichia pastoris; Saccharomyces cerevisiae; therapeutic proteins; yeast

Indexed keywords

GLYCAN DERIVATIVE; GLYCOPROTEIN; POLYSACCHARIDE; RECOMBINANT PROTEIN;

ARTICLE; BIOSYNTHESIS; ENZYME REPLACEMENT; GLYCOSYLATION; HUMAN; INTERVENTION STUDY; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; STRUCTURE ACTIVITY RELATION; YEAST; GENETIC ENGINEERING; GENETICS; SACCHAROMYCES CEREVISIAE; TRANSGENIC ORGANISM;

MAMMALIA; PICHIA PASTORIS; SACCHAROMYCES CEREVISIAE;

GENETIC ENGINEERING; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; ORGANISMS, GENETICALLY MODIFIED; POLYSACCHARIDES; RECOMBINANT PROTEINS; SACCHAROMYCES CEREVISIAE; YEASTS;

EID: 84921504334     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.104     Document Type: Article

References (68)

1. Nielsen J. Production of biopharmaceutical proteins by yeast: advances through metabolic engineering. Bioengineered 4(4), 207-211 (2013).
2. González M, Brito N, González C. High abundance of Serine/Threonine-rich regions predicted to be hyper-O-glycosylated in the secretory proteins coded by eight fungal genomes. BMC Microbiol. 12, 213 (2012).
3. Walsh G. Biopharmaceutical benchmarks 2010. Nat. Biotechnol. 28(9), 917-924 (2010).
4. Solá RJ, Griebenow K. Glycosylation of therapeutic proteins: an effective strategy to optimize efficacy. BioDrugs Clin. Immunother. Biopharm. Gene Ther. 24(1), 9-21 (2010).
5. Hossler P. Protein glycosylation control in mammalian cell culture: past precedents and contemporary prospects. Adv. Biochem. Eng. Biotechnol. 127, 187-219 (2012).
6. Li H, d'Anjou M. Pharmacological significance of glycosylation in therapeutic proteins. Curr. Opin. Biotechnol. 20(6), 678-684 (2009).
7. Helenius A, Aebi M. Roles of N-linked glycans in the endoplasmic reticulum. Annu. Rev. Biochem. 73, 1019-1049 (2004).
8. Moremen KW, Tiemeyer M, Nairn AV. Vertebrate protein glycosylation: diversity, synthesis and function. Nat. Rev. Mol. Cell Biol. 13(7), 448-462 (2012).
9. Dean N. Asparagine-linked glycosylation in the yeast Golgi. Biochim. Biophys. Acta 1426(2), 309-322 (1999).
10. Han Y, Kanbe T, Cherniak R, Cutler JE. Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. Infect. Immun. 65(10), 4100-4107 (1997).
11. Gemmill TR, Trimble RB. Overview of N-and O-linked oligosaccharide structures found in various yeast species. Biochim. Biophys. Acta 1426(2), 227-237 (1999).
12. Lommel M, Strahl S. Protein O-mannosylation: conserved from bacteria to humans. Glycobiology 19(8), 816-828 (2009).
13. Luong M, Lam JS, Chen J, Levitz SM. Effects of fungal N-and O-linked mannosylation on the immunogenicity of model vaccines. Vaccine 25(22), 4340-4344 (2007).
14. Lam JS, Mansour MK, Specht CA, Levitz SM. A model vaccine exploiting fungal mannosylation to increase antigen immunogenicity. J. Immunol. 175(11), 7496-7503 (2005).
15. Zhang N, Liu L, Dumitru CD et al. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. mAbs 3(3), 289-298 (2011).
16. Higgins E. Carbohydrate analysis throughout the development of a protein therapeutic. Glycoconj. J. 27(2), 211-225 (2010).
17. Nakayama K, Nagasu T, Shimma Y, Kuromitsu J, Jigami Y. OCH1 encodes a novel membrane bound mannosyltransferase: outer chain elongation of asparagine-linked oligosaccharides. EMBO J. 11(7), 2511-2519 (1992).
18. Nakanishi-Shindo Y, Nakayama K, Tanaka A, Toda Y, Jigami Y. Structure of the N-linked oligosaccharides that show the complete loss of alpha-1,6-polymannose outer chain from och1, och1 mnn1 and och1 mnn1 alg3 mutants of Saccharomyces cerevisiae. J. Biol. Chem. 268(35), 26338-26345 (1993).
19. Chiba Y, Suzuki M, Yoshida S et al. Production of human compatible high mannose-type (Man5GlcNAc2) sugar chains in Saccharomyces cerevisiae. J. Biol. Chem. 273(41), 26298-26304 (1998).
20. Abe H, Takaoka Y, Chiba Y et al. Development of valuable yeast strains using a novel mutagenesis technique for the effective production of therapeutic glycoproteins. Glycobiology 19(4), 428-436 (2009).
21. Hamilton SR, Davidson RC, Sethuraman N et al. Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 313(5792), 1441-1443 (2006).
22. De Pourcq K, Vervecken W, Dewerte I, Valevska A, Van Hecke A, Callewaert N. Engineering the yeast Yarrowia lipolytica for the production of therapeutic proteins homogeneously glycosylated with Man8GlcNAc2 and Man5GlcNAc2. Microb. Cell Factories 11, 53 (2012).
23. Ohashi T, Takegawa K. N-and O-linked oligosaccharides completely lack galactose residues in the gms1och1 mutant of Schizosaccharomyces pombe. Appl. Microbiol. Biotechnol. 86(1), 263-272 (2010).
24. Ohashi T, Fujiyama K, Takegawa K. Identification of novel 1,3-galactosyltransferase and elimination of á-galactose-containing glycans by disruption of multiple galactosyltransferase genes in Schizosaccharomyces pombe. J. Biol. Chem. 287(46), 38866-38875 (2012).
25. Vervecken W, Kaigorodov V, Callewaert N, Geysens S, De Vusser K, Contreras R. In vivo synthesis of mammalian-like, hybrid-type N-glycans in Pichia pastoris. Appl. Environ. Microbiol. 70(5), 2639-2646 (2004).
26. Choi B-K, Bobrowicz P, Davidson RC et al. Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris. Proc. Natl Acad. Sci. USA 100(9), 5022-5027 (2003).
27. Kim MW, Kim EJ, Kim J-Y et al. Functional characterization of the Hansenula polymorpha HOC1, OCH1 and OCR1 genes as members of the yeast OCH1 mannosyltransferase family involved in protein glycosylation. J. Biol. Chem. 281(10), 6261-6272 (2006).
28. Hamilton SR, Bobrowicz P, Bobrowicz B et al. Production of complex human glycoproteins in yeast. Science 301(5637), 1244-1246 (2003).
29. Bobrowicz P, Davidson RC, Li H et al. Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose. Glycobiology 14(9), 757-766 (2004).
30. Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-engineering. mAbs 4(4), 419-425 (2012).
31. Ha S, Wang Y, Rustandi RR. Biochemical and biophysical characterization of humanized IgG1 produced in Pichia pastoris. mAbs 3(5), 453-460 (2011). 32 Zha D. US/0313137 A1 (2011).
32. Jacobs PP, Geysens S, Vervecken W, Contreras R, Callewaert N. Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology. Nat. Protoc. 4(1), 58-70 (2009).
33. Nett JH, Gomathinayagam S, Hamilton SR et al. Optimization of erythropoietin production with controlled glycosylation-PEGylated erythropoietin produced in glycoengineered Pichia pastoris. J. Biotechnol. 157(1), 198-206 (2012).
34. Merck Sharp and Dhome., WO/046855 (2011).
35. De Pourcq K, Tiels P, Van Hecke A, Geysens S, Vervecken W, Callewaert N. Engineering Yarrowia lipolytica to produce glycoproteins homogeneously modified with the universal Man3GlcNAc2 N-glycan core. PLoS ONE 7(6), e39976 (2012).
36. Oh D-B, Park J-S, Kim MW et al. Glycoengineering of the methylotrophic yeast Hansenula polymorpha for the production of glycoproteins with trimannosyl core N-glycan by blocking core oligosaccharide assembly. Biotechnol. J. 3(5), 659-668 (2008).
37. Davidson RC, Nett JH, Renfer E et al. Functional analysis of the ALG3 gene encoding the Dol-P-Man: Man5GlcNAc2-PP-Dol mannosyltransferase enzyme of P. pastoris. Glycobiology 14(5), 399-407 (2004).
38. Verostek MF, Atkinson PH, Trimble RB. Structure of Saccharomyces cerevisiae alg3, sec18 mutant oligosaccharides. J. Biol. Chem. 266(9), 5547-5551 (1991).
39. Vella GJ, Paulsen H, Schachter H. Control of glycoprotein synthesis. IX. A terminal Man alpha l-3Man beta 1-sequence in the substrate is the minimum requirement for UDP-N-acetyl-D-glucosamine: alpha-D-mannoside (GlcNAc to Man alpha 1-3) beta 2-N-acetylglucosaminyltransferase I. Can. J. Biochem Cell Biol. 62(6), 409-417 (1984).
40. Narasimhan S, Stanley P, Schachter H. Control of glycoprotein synthesis. Lectin-resistant mutant containing only one of two distinct N-acetylglucosaminyltransferase activities present in wild type Chinese hamster ovary cells. J. Biol. Chem. 252(11), 3926-3933 (1977).
41. Cheon SA, Kim H, Oh D-B, Kwon O, Kang HA. Remodeling of the glycosylation pathway in the methylotrophic yeast Hansenula polymorpha to produce human hybrid-type N-glycans. J. Microbiol. Seoul Korea. 50(2), 341-348 (2012).
42. Helenius J, Ng DTW, Marolda CL, Walter P, Valvano MA, Aebi M. Translocation of lipid-linked oligosaccharides across the ER membrane requires Rft1 protein. Nature 415(6870), 447-450 (2002).
43. Song H, Qian W, Wang H, Qiu B. Identification and functional characterization of the HpALG11 and the HpRFT1 genes involved in N-linked glycosylation in the methylotrophic yeast Hansenula polymorpha. Glycobiology 20(12), 1665-1674 (2010).
44. Wang H, Song H-L, Wang Q, Qiu B-S. Expression of glycoproteins bearing complex human-like glycans with galactose terminal in Hansenula polymorpha. World J. Microbiol. Biotechnol. 29(3), 447-458 (2013).
45. Choi B-K, Warburton S, Lin H et al. Improvement of N-glycan site occupancy of therapeutic glycoproteins produced in Pichia pastoris. Appl. Microbiol. Biotechnol. 95(3), 671-682 (2012).
46. Piirainen MA, de Ruijter JC, Koskela EV, Frey AD. Glycoengineering of yeasts from the perspective of glycosylation efficiency. New Biotechnol. 31(6), 532-537 (2014).
47. Parsaie Nasab F, Aebi M, Bernhard G, Frey AD. A combined system for engineering glycosylation efficiency and glycan structure in Saccharomyces cerevisiae. Appl. Environ. Microbiol. 79(3), 997-1007 (2013).
48. Odani T, Shimma Y, Tanaka A, Jigami Y. Cloning and analysis of the MNN4 gene required for phosphorylation of N-linked oligosaccharides in Saccharomyces cerevisiae. Glycobiology 6(8), 805-810 (1996).
49. Park J-N, Song Y, Cheon SA et al. Essential role of YlMPO1, a novel Yarrowia lipolytica homologue of Saccharomyces cerevisiaeMNN4, in mannosylphosphorylation of N-and O-linked glycans. Appl. Environ. Microbiol. 77(4), 1187-1195 (2011).
50. Akeboshi H, Kasahara Y, Tsuji D et al. Production of human beta-hexosaminidase A with highly phosphorylated N-glycans by the overexpression of the Ogataea minutaMNN4 gene. Glycobiology 19(9), 1002-1009 (2009).
51. Tiels P, Baranova E, Piens K et al. A bacterial glycosidase enables mannose-6-phosphate modification and improved cellular uptake of yeast-produced recombinant human lysosomal enzymes. Nat. Biotechnol. 30(12), 1225-1231 (2012).
52. Chiba Y, Sakuraba H, Kotani M et al. Production in yeast of galactosidase A, a lysosomal enzyme applicable to enzyme replacement therapy for Fabry disease. Glycobiology 12(12), 821-828 (2002).
53. Govindappa N, Hanumanthappa M, Venkatarangaiah K et al. PMT1 gene plays a major role in O-mannosylation of insulin precursor in Pichia pastoris. Protein Expr. Purif. 88(1), 164-171 (2013).
54. Nett JH, Cook WJ, Chen M-T et al. Characterization of the Pichia pastoris protein-O-mannosyltransferase gene family. PLoS ONE 8(7), e68325 (2013).
55. Orchard MG, Neuss JC, Galley CMS et al. Rhodanine-3-acetic acid derivatives as inhibitors of fungal protein mannosyl transferase 1 (PMT1). Bioorg. Med. Chem. Lett. 14(15), 3975-3978 (2004).
56. Arroyo J, Hutzler J, Bermejo C et al. Functional and genomic analyses of blocked protein O-mannosylation in baker's yeast. Mol. Microbiol. 79(6), 1529-1546 (2011).
57. Hopkins D, Gomathinayagam S, Rittenhour AM et al. Elimination of mannose glycan structures in Pichia pastoris. Glycobiology 21(12), 1616-1626 (2011).
58. Gomathinayagam S, Hamilton SR. In vitro enzymatic treatment to remove O-linked mannose from intact glycoproteins. Appl. Microbiol. Biotechnol. 98(6), 2545-2554 (2014).
59. Pastores DGM. Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease. BioDrugs 24(1), 41-47 (2010).
60. Hamilton SR, Cook WJ, Gomathinayagam S et al. Production of sialylated O-linked glycans in Pichia pastoris. Glycobiology 23(10), 1192-1203 (2013).
61. Liu L, Gomathinayagam S, Hamuro L et al. The impact of glycosylation on the pharmacokinetics of a TNFR2:Fc fusion protein expressed in Glycoengineered Pichia pastoris. Pharm. Res. 30(3), 803-812 (2013).
62. Amano K, Chiba Y, Kasahara Y et al. Engineering of mucin-type human glycoproteins in yeast cells. Proc. Natl Acad. Sci. USA 105(9), 3232-3237 (2008).
63. Chigira Y, Oka T, Okajima T, Jigami Y. Engineering of a mammalian O-glycosylation pathway in the yeast Saccharomyces cerevisiae: Production of O-fucosylated epidermal growth factor domains. Glycobiology 18(4), 303-314 (2008).
64. Nakayama K, Maeda Y, Jigami Y. Interaction of GDP-4-keto-6-deoxymannose-3,5-epimerase-4-reductase with GDP-mannose-4,6-dehydratase stabilizes the enzyme activity for formation of GDP-fucose from GDP-mannose. Glycobiology 13(10), 673-680 (2003).
65. Kimura T, Finn OJ. MUC1 immunotherapy is here to stay. Expert Opin. Biol. Ther. 13(1), 35-49 (2013).
66. Freire-de-Lima L. Sweet and Sour: The impact of differential glycosylation in cancer cells undergoing epithelial-mesenchymal transition. Front. Oncol. 4, 59 (2014).
67. Ratner M. Genentech's glyco-engineered antibody to succeed Rituxan. Nat. Biotechnol. 32(1), 6-7 (2014).
68. Wang C-C, Chen J-R, Tseng Y-C et al. Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc. Natl Acad. Sci. USA 106(43), 18137-18142 (2009).